In This Section      
 

Ciccarone Articles

Ciccarone Center Research

Topic

Diabetes & Metabolic Syndrome

Landmark Articles

Implementing and evaluating a multicomponent inpatient diabetes management program: putting research into practice.
By: Munoz M, Pronovost P, Dintzis J, Kemmerer T, Wang NY, Chang YT, Efird L, Berenholtz SM, Golden SH.
Inpatient glucose management remains an important area for patient safety, quality improvement, and clinical research, and the implementation model should guide other hospitals in their glucose management initiatives.
Read on Pubmed
Metabolic syndrome, diabetes, and incidence and progression of coronary calcium: the Multi-Ethnic Study of Atherosclerosis study.
By: Wong ND, Nelson JC, Granston T, Bertoni AG, Blumenthal RS, Carr JJ, Guerci A, Jacobs DR Jr, Kronmal R, Liu K, Saad M, Selvin E, Tracy R, Detrano R.
This study examines and compares the incidence and progression of CAC among persons with metabolic syndrome and diabetes mellitus (DM) versus those with neither condition. Individuals with metabolic syndrome and DM have a greater incidence and absolute progression of CAC compared with individuals without these conditions, with progression also predicting coronary heart disease events in those with metabolic syndrome and DM.
Read on Pubmed
Statins and diabetes: rethinking the data.
By: Minder CM, Santos RD, Blumenthal RS.

This article briefly reviews the key evidence linking statins with new-onset diabetes and highlight the relative strengths and weaknesses of existing studies. We also offer clinical insight to help health care providers weigh the potential risks and benefits of statin therapy.

Potential implications of coronary artery calcium testing for guiding aspirin use among asymptomatic individuals with diabetes.
By: Silverman MG, Blaha MJ, Budoff MJ, Rivera JJ, Raggi P, Shaw LJ, Berman D, Callister T, Rumberger JA, Rana JS, Blumenthal RS, Nasir K.
We conclude that CAC can help risk stratify individuals with diabetes and may aid in selection of patients who may benefit from therapies such as low-dose aspirin for primary prevention of CVD.
Read on Pubmed
Associations of salivary cortisol levels with metabolic syndrome and its components: the multi-ethnic study of atherosclerosis.
By: DeSantis AS, DiezRoux AV, Hajat A, Golden SH, Jenny NS, Sanchez BN, Shea S, Seeman TE.
Our findings do not support the hypothesis that differences in level or diurnal pattern of salivary cortisol output are associated with metabolic syndrome among persons without clinical diabetes.
Read on Pubmed
The relationship of insulin resistance and extracoronary calcification in the multi-ethnic study of atherosclerosis.
By: Tison GH, Blaha MJ, Budoff MJ, Katz R, Rivera JJ, Bertoni AG, Wong ND, Blumenthal RS, Szklo M, Eng J, Tracy R, Nasir K.
The homeostasis model assessment of insulin resistance has a positive and graded association with extra-coronary calcification, but not independently of cardiovascular risk factors, particularly metabolic syndrome components.
Read on Pubmed
Impact of subclinical atherosclerosis on cardiovascular disease events in individuals with metabolic syndrome and diabetes: the multi-ethnic study of atherosclerosis.
By: Malik S, Budoff MJ, Katz R, Blumenthal RS, Bertoni AG, Nasir K, Szklo M, Barr RG, Wong ND.
Individuals with metabolic syndrome or diabetes have low risks for CHD when CAC or carotid intimal-medial thickness (CIMT) is not increased. Prediction of CHD and CVD events is improved by CAC more than by CIMT. Screening for CAC or CIMT can stratify risk in people with metabolic syndrome and diabetes and support the latest recommendations regarding CAC screening in those with diabetes.
Read on Pubmed
Statin therapy dose and risk of new-onset diabetes.
By: McEvoy JW.
Read on Pubmed
Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation.
By: Ndumele CE, Nasir K, Conceiçao RD, Carvalho JA, Blumenthal RS, Santos RD.
The goal of this study was to assess the independent and collective associations of hepatic steatosis, obesity, and the metabolic syndrome with elevated hsCRP levels. We evaluated 2,388 individuals without clinical cardiovascular disease between December 2004 and December 2006. Hepatic steatosis was diagnosed by ultrasound, and the metabolic syndrome was defined using National Heart, Lung, and Blood Institute criteria. We concluded that hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased odds of high hsCRP levels.
Read on Pubmed
Impact of subclinical atherosclerosis on cardiovascular disease events in individuals with metabolic syndrome and diabetes: The multi-ethnic study of atherosclerosis.
By: Malik S, Budoff MJ, Katz R, Blumenthal RS, Bertoni AG, Nasir K, Szklo M, Barr RG, Wong ND.
While metabolic syndrome and diabetes generally confer a greater cardiovascular disease (CVD) risk, recent evidence suggests that these individuals have a wide range of risk. We evaluated whether screening for CAC and carotid intimal medial thickness (CIMT) can improve CVD risk stratification over traditional risk factors (RFs) in people with metabolic syndrome and diabetes. We concluded that individuals with metabolic syndrome or diabetes have low risks for CHD when CAC or CIMT is not increased. Prediction of CHD and CVD events are improved by CAC more than by CIMT. Screening for CAC or CIMT can stratify risk in people with metabolic syndrome and diabetes and support the latest recommendations regarding CAC screening in those with diabetes.
Read on Pubmed